Tags

Type your tag names separated by a space and hit enter

Remdesivir for COVID-19: challenges of underpowered studies.
Lancet. 2020 05 16; 395(10236):1525-1527.Lct

Authors+Show Affiliations

Edinburgh Clinical Trials Unit, Usher Institute, Edinburgh EH16 4UX, UK. Electronic address: j.norrie@ed.ac.uk.

Pub Type(s)

Journal Article
Comment

Language

eng

PubMed ID

32423580

Citation

Norrie, John David. "Remdesivir for COVID-19: Challenges of Underpowered Studies." Lancet (London, England), vol. 395, no. 10236, 2020, pp. 1525-1527.
Norrie JD. Remdesivir for COVID-19: challenges of underpowered studies. Lancet. 2020;395(10236):1525-1527.
Norrie, J. D. (2020). Remdesivir for COVID-19: challenges of underpowered studies. Lancet (London, England), 395(10236), 1525-1527. https://doi.org/10.1016/S0140-6736(20)31023-0
Norrie JD. Remdesivir for COVID-19: Challenges of Underpowered Studies. Lancet. 2020 05 16;395(10236):1525-1527. PubMed PMID: 32423580.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Remdesivir for COVID-19: challenges of underpowered studies. A1 - Norrie,John David, Y1 - 2020/04/29/ PY - 2020/04/26/received PY - 2020/04/27/accepted PY - 2020/5/20/entrez PY - 2020/5/20/pubmed PY - 2020/5/30/medline SP - 1525 EP - 1527 JF - Lancet (London, England) JO - Lancet VL - 395 IS - 10236 SN - 1474-547X UR - https://www.unboundmedicine.com/medline/citation/32423580/full_citation L2 - https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(20)31023-0 DB - PRIME DP - Unbound Medicine ER -